Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic myelogenous leukemia].

K Ohnishi1

  • 1Department of Medicine III, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Restoration by glycerol of p53-dependent apoptosis in cells bearing the mutant p53 gene.

International journal of radiation biology·1999
Same author

Regeneration of transected spinal cord in young adult rats using freeze-dried alginate gel.

Neuroreport·1999
Same author

Generalized eruptive histiocytoma of childhood associated with rheumatic fever.

European journal of dermatology : EJD·1999
Same author

Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.

The American journal of surgical pathology·1999
Same author

The protein kinase inhibitor, H-7, suppresses heat induced activation of heat shock transcription factor 1.

Molecular and cellular biochemistry·1999
Same author

Serum levels of vascular cell adhesion molecule-1 (VCAM-1) in acute Q fever.

Annals of tropical medicine and parasitology·1999
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

STI571, a targeted therapy, shows promise for chronic myelogenous leukemia (CML) and Ph+ ALL, with high response rates. Risk assessment guides treatment choices between stem cell transplantation and interferon-alpha therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Context:

  • Chronic myelogenous leukemia (CML) treatment landscape.
  • Emergence of molecular targeted therapy.
  • Limited options for advanced CML phases.

Purpose:

  • Evaluate STI571 (imatinib) as a novel molecular targeted therapy for CML.
  • Compare efficacy and survival outcomes of stem cell transplantation (SCT) versus interferon-alpha (IFN-alpha) therapy.
  • Determine optimal treatment strategies based on patient risk stratification.

Summary:

  • STI571, a BCA-ABL tyrosine kinase inhibitor, demonstrated minimal adverse effects in Phase I studies.
  • High complete hematologic response (98%) and significant cytogenetic response (31%) observed in chronic phase CML patients with daily STI571 doses (≥300 mg).

Related Experiment Videos

  • STI571 exhibits substantial activity in blast crisis CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
  • Risk assessment analyses indicate SCT improves survival in younger, intermediate/high-risk CML patients, but not older, high-risk patients compared to IFN-alpha.
  • A Japanese prospective study showed SCT survival was not superior to IFN-alpha in older, high-risk patients.

    • Impact:

    • STI571 represents a significant advancement in molecular targeted therapy for CML.
    • Individualized risk assessment is crucial for selecting between SCT and IFN-alpha in chronic phase CML.
    • Establishes a basis for personalized medicine approaches in hematologic malignancies.